Several guidelines (Brahmer et al. 2018; Puzanov et al. 2017; Haanen et al. 2022) recommend immunomodulatory agents, such as TNF-α inhibitors, anti-IL-6, and intravenous immunoglobulin (IVIG), as second-line treatment for steroid-refractory ICI-pneumonitis. The gene discussed is TNF; the disease is pneumonitis.